Estrella Immunopharma, Inc. — fact timeline

Estrella Immunopharma, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“January 7, 2026, Estrella Immunopharma, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a) because the Company has not held an annual meeting of shareholders within the required time period. The Letter also referenced the compliance plan procedures under Nasdaq Listing Rule 5810(c)(2)(G). The Letter states that the Company has 45 calendar days to submit a plan to regain compliance. The Company intends to submit its compliance”

Estrella Immunopharma, Inc. issued an aggregate of 7,594,935 shares of Common Stock of warrant to a healthcare-focused institutional investor for $1.39 per share.

“Direct Offering, the “Offerings”), common stock purchase warrants (the “PIPE Common Warrants”), exercisable for up to an aggregate of 7,594,935 shares of Common Stock for $1.39 per share, subject to customary anti-dilution adjustments for stock splits, reclassifications and recapitalizations of the Company’s Common Stock. Each Share will be accompanied”

Estrella Immunopharma, Inc. entered into Registration Rights Agreement with the Investor (effective 2026-01-05).

“In connection with the Private Placement, the Company and the Investor entered into a registration rights agreement, dated January 5, 2026 (the “Registration Rights Agreement”), pursuant to which the Company agreed to file a registration statement (the “Resale Registration Statement”), providing for the resale of the shares of Common Stock issued and issuable upon exercise of the PIPE Common Warrants within thirty (30) days of the closing of the Offering, to have such registration statement declared effective within sixty (60) days of the closing date (or ninety (90) days of the closing date if the SEC conducts a full review of a Resale Registration Statement), and to maintain the effectiveness of such registration statement until the earlier of (i) the date on which all such securities have been sold thereunder or pursuant to Rule 144, or (ii) the date on which such securities are eligible for resale without the need for registration under the Securities Act.”

Estrella Immunopharma, Inc. entered into Placement Agent Agreement with Aegis Capital Corp. (effective 2026-01-05).

“In connection with the Offerings, the Company also entered into a placement agent agreement, dated January 5, 2026 (the “Placement Agent Agreement”), with Aegis Capital Corp. (the “Placement Agent”), pursuant to which the Company paid the Placement Agent a cash fee equal to 6.0% of the aggregate gross proceeds of the Offerings and reimbursed the Placement Agent for certain expenses and legal fees.”

Estrella Immunopharma, Inc. entered into Securities Purchase Agreement with a healthcare-focused institutional investor valued at approximately $8.0 million (effective 2026-01-05).

“On January 5, 2026, Estrella Immunopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with a healthcare-focused institutional investor (the “Investor”), pursuant to which the Company agreed to issue and sell to the Investor (a) in a registered direct offering (the “Registered Direct Offering”) (i) 4,063,290 shares (the “Shares”) of common stock, par value $0.0001 per share (“Common Stock”), of the Company, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 1,000,000 shares of Common Stock for $0.00001 per share; and (b) in a concurrent private placement (the “Private Placement,” and together with the Registered Direct Offering, the “Offerings”), common stock purchase warrants (the “PIPE Common Warrants”), exercisable for up to an aggregate of 7,594,935 shares of Common Stock for $1.39 per share, subject to customary anti-dilution adjustments for stock splits, reclassifications and recapitalizations of the Co”

Estrella Immunopharma, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“August 1, 2025, Estrella Immunopharma, Inc. (the “ Company ”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(2), which requires listed securities to maintain a minimum Market Value of Listed Securities (“ MVLS ”) of $35,000,000. The Company has not met this requirement for the 30 consecutive business days preceding the date of the notice. The notice indicated the period of non-compliance was from June 13, 2025, to July 31, 2025. The notice also not”

Estrella Immunopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 28, 2025, the common stock of the Company had not maintained a minimum closing bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until April 30, 2024 (the “Compliance Period”), to regain compliance with the Bid Price Rule. If the Company does not regain compliance with the Bid Price Rule by October 27, 2025, the Company may be eligible for an additional 180-day period to”

Estrella Immunopharma, Inc.: Changed fiscal year end from June 30 to December 31 (effective 2024-11-25).

“On November 25, 2024, in order to align the fiscal year of Estrella Immunopharma, Inc. (the “ Company ”) with the calendar year and facilitate the Company’s accounting and reporting processes, the Board of Directors of the Company approved a change in the Company’s fiscal year end from June 30 to December 31.”

Hong Zhang was appointed as Chairperson and a member of the Board of Directors at Estrella Immunopharma, Inc..

“On August 14, 2024, the Board of Directors of Estrella Immunopharma, Inc. (the “Company”) appointed Ms. Hong Zhang as Chairperson and a member of the Company’s Board of Directors (the “Board”), effective as of the same date.”

Estrella Immunopharma, Inc. amended Amendment No. 1 to the Statement of Work with Eureka Therapeutics, Inc. (effective 2024-03-04).

“On May 13, 2024, Estrella Immunopharma, Inc. (the “Company”), Estrella Biopharma, Inc. (“Estrella”), a wholly-owned subsidiary of the Company and the sole operating subsidiary of the Company, and Eureka Therapeutics, Inc. (“Eureka”), the controlling shareholder of the Company, entered into Amendment No. 1 to the Statement of Work (“Amendment No. 1”), effective as of March 4, 2024, which amends Statement of Work #001 (the “SOW”), dated and effective as of March 4, 2024, among the Company, Estrella, and Eureka, relating to the services (“Services”) to be performed by Eureka for Estrella in connection with Estrella’s EB103 anti-CD19 ARTEMIS® clinical trial.”

Estrella Immunopharma, Inc. engaged Macias Gini & O’Connell, LLP as its auditor.

“appointed Macias Gini & O’Connell, LLP ("MGO") as the Company’s new independent registered public accounting firm for the fiscal year ending June 30, 2024, effective as of January 30, 2024.”

Estrella Immunopharma, Inc. dismissed Marcum LLP as its auditor.

“dismissed its independent registered public accountant Marcum LLP ("Marcum"), effective as of January 30, 2024.”

Estrella Immunopharma, Inc.: Fiscal year end changed from December 31 to June 30 effective as of the closing date of the Business Combination (effective 2023-09-29).

“Effective as of the closing date of the Business Combination on September 29, 2023, the Company’s fiscal year end changed from December 31 to June 30.”

Estrella Immunopharma, Inc.: Upon the Closing, New Estrella ceased to be a shell company.

“Upon the Closing, New Estrella ceased to be a shell company.”

Estrella Immunopharma, Inc.: Board of directors approved and adopted a new Code of Ethics applicable to directors, officers and employees in connection with the Closing (effective 2023-09-29).

“In connection with the Closing, the board of directors of New Estrella approved and adopted a new Code of Ethics applicable to directors, officers and employees.”

Estrella Immunopharma, Inc.: New amended and restated bylaws (New Bylaws) approved and adopted by board of directors, effective as of the Effective Time (September 29, 2023) (effective 2023-09-29).

“On September 29, 2023, the board of directors of New Estrella approved and adopted the New Bylaws, which became effective as of the Effective Time.”

Estrella Immunopharma, Inc.: Amended and restated certificate of incorporation (New Charter) approved at special meeting and effective upon filing with Secretary of State of Delaware on September 29, 2023 (effective 2023-09-29).

“The New Charter, which became effective upon filing with the Secretary of State of the State of Delaware on September 29, 2023, includes the amendments proposed by the Charter Proposal and approved at the Special Meeting.”

Estrella Immunopharma, Inc. underwent a change of control involving TradeUP Acquisition Corp. for $325,000,000 (closed 2023-09-29).

“from UPTD, in the aggregate, a number of newly issued shares of common stock of New Estrella (as defined below), par value $0.0001 per share (“Common Stock”) equal to: (i) $325,000,000 (the “Merger Consideration”), divided by (ii) $10.00 per share (such shares of Common Stock is referred as “Merger Consideration Shares”) in consideration of converting their”

Estrella Immunopharma, Inc. entered into Subscription Agreements with Plentiful Limited and Lianhe World Limited valued at $5,000,000 shares (effective 2023-09-14).

“On September 14, 2023, TradeUP Acquisition Corp. (the “Company” or “UPTD”) entered into subscription agreements (the “Subscription Agreements”) with each of Plentiful Limited, a Samoan limited company (“Plentiful Limited”) and Lianhe World Limited, a company incorporated in the People’s Republic of China (“Lianhe World” and together with Plentiful Limited, the “Investors”)”

Estrella Immunopharma, Inc. incurred loan of $37,432.70 with Estrella at no interest maturing upon the consummation of the Company's business combination.

“Estrella has deposited a monthly extension payment of $37,432.70 to the trust account of the Company to extend the deadline for the Company to complete the business combination contemplated therein by October 19, 2023. Such deposit is evidenced by an unsecured promissory note in the principal amount of $37,432.70 issued by the Company to Estrella (the “Extension Note”).”

Estrella Immunopharma, Inc. incurred loan of $37,432.70 with Estrella Biopharma, Inc. at no interest maturing upon the consummation of the Company’s business combination.

“Estrella has deposited a monthly extension payment of $37,432.70 to the trust account of the Company to extend the deadline for the Company to complete the business combination contemplated therein by September 19, 2023. Such deposit is evidenced by an unsecured promissory note in the principal amount of $37,432.70 issued by the Company to Estrella (the “Extension Note”).”

Estrella Immunopharma, Inc. shareholders approved Approve the Estrella Immunopharma, Inc. 2023 Omnibus Incentive Plan at the 2023-07-31 meeting.

“The stockholders approved the Estrella Immunopharma, Inc. 2023 Omnibus Incentive Plan, which will become effective as of and is contingent on the consummation of the Business Combination. The voting results were as follows: FOR AGAINT ABSTAIN BROKER NON-VOTE 1,884,258 631 0 N/A”

Estrella Immunopharma, Inc. shareholders approved Appointment of five directors: Dr. Cheng Liu, Dr. Marsha Roberts, Mr. Fan Wu, Ms. Janelle Wu, Ms. Pei Xu as Class II and Class III directors at the 2023-07-31 meeting.

“The stockholders approved the appointment of five directors who, upon consummation of the Business Combination, will become directors of the Combined Company. Specifically, appoint each of Dr. Marsha Roberts, Mr. Fan Wu, and Ms. Janelle Wu as Class II director and each of Dr. Cheng Liu and Ms. Pei Xu as Class III director. The voting results for each director nominee were as follows: (1) Dr. Cheng Liu FOR AGAINT ABSTAIN BROKER NON-VOTE 1,884,258 0 631 N/A (2) Dr. Marsha Roberts FOR AGAINT ABSTAIN BROKER NON-VOTE 1,884,258 0 631 N/A (3) Mr. Fan Wu FOR AGAINT ABSTAIN BROKER NON-VOTE 1,884,258 0 631 N/A (4) Ms. Janelle Wu FOR AGAINT ABSTAIN BROKER NON-VOTE 1,884,258 0 631 N/A (5) Ms. Pei Xu FOR AGAINT ABSTAIN BROKER NON-VOTE 1,884,258 0 631 N/A”

Estrella Immunopharma, Inc. shareholders approved Approve issuance of 32,500,000 shares of common stock in connection with the Business Combination and at least 1,500,000 shares in connection with Merger Financing for purposes of complying with Nasdaq Listing Rule 5635 at the 2023-07-31 meeting.

“The stockholders approved, for purposes of complying with the applicable provisions of Nasdaq Listing Rule 5635, the issuance of 32,500,000 shares of common stock of the Company in connection with the Business Combination and the issuance of at least 1,500,000 shares of common stock of the Company in connection with satisfying the Merger Financing closing condition to certain investors, if any, prior to or at the Closing, which amount will be determined as described in more detail in the Definitive Proxy Statement. The voting results were as follows: FOR AGAINT ABSTAIN BROKER NON-VOTE 1,884,258 631 0 N/A”

Estrella Immunopharma, Inc. shareholders approved Advisory Charter Amendment Proposals: (f) make the Combined Company’s corporate existence perpetual and omit SPAC provisions at the 2023-07-31 meeting.

“(6) Proposal 3(f) – to make the Combined Company’s corporate existence perpetual instead of requiring UPTD to be dissolved and liquidated 18 months following the closing of the initial public offering of the Company, and to omit from the Proposed Charter the various provisions applicable only to special purpose acquisition companies. FOR AGAINT ABSTAIN BROKER NON-VOTE 1,884,258 631 0 N/A”

Estrella Immunopharma, Inc. shareholders approved Advisory Charter Amendment Proposals: (e) provide that certain amendments to provisions of the Proposed Charter will require supermajority approval at the 2023-07-31 meeting.

“(5) Proposal 3(e) – to provide that certain amendments to provisions of the Proposed Charter will require the approval of the holders of at least two-thirds (66 and 2/3%) of the Combined Company’s then-outstanding shares of capital stock entitled to vote on such amendments, and of the holders of shares of each class entitled to vote thereon as a class; and FOR AGAINT ABSTAIN BROKER NON-VOTE 1,884,258 631 0 N/A”

Estrella Immunopharma, Inc. shareholders approved Advisory Charter Amendment Proposals: (d) provide that certain named individuals be elected to serve as Class I, Class II, and Class III directors and removal provisions at the 2023-07-31 meeting.

“(4) Proposal 3(d) – to provide that certain named individuals be elected to serve as Class I, Class II, and Class III directors to serve staggered terms on the board of directors of the Combined Company until their respective successors are duly elected and qualified, or until their earlier resignation, death, or removal, and to provide that the removal of any director be only for cause and only by the affirmative vote of the holders of at least two-thirds (66 and 2/3%) of the Combined Company’s then-outstanding shares of capital stock entitled to vote at an election of directors; FOR AGAINT ABSTAIN BROKER NON-VOTE 1,884,258 631 0 N/A”

Estrella Immunopharma, Inc. shareholders approved Advisory Charter Amendment Proposals: (c) increase the authorized shares of preferred stock to 10,000,000 shares of preferred stock at the 2023-07-31 meeting.

“(3) Proposal 3(c) – to increase the authorized shares of preferred stock to 10,000,000 shares of preferred stock, par value of $0.0001 per share; FOR AGAINT ABSTAIN BROKER NON-VOTE 1,884,258 631 0 N/A”

Estrella Immunopharma, Inc. shareholders approved Advisory Charter Amendment Proposals: (b) increase the authorized shares of common stock of the Combined Company to 250,000,000 shares of common stock at the 2023-07-31 meeting.

“(2) Proposal 3(b) – to increase the authorized shares of common stock of the Combined Company to 250,000,000 shares of common stock, par value of $0.0001 per share; FOR AGAINT ABSTAIN BROKER NON-VOTE 1,884,258 631 0 N/A”

Estrella Immunopharma, Inc. shareholders approved Advisory Charter Amendment Proposals: (a) change the corporate name of the Combined Company to Estrella Immunopharma, Inc. at the 2023-07-31 meeting.

“(1) Proposal 3(a) – to change the corporate name of the Combined Company to “Estrella Immunopharma, Inc.” on and from the time of the Business Combination; FOR AGAINT ABSTAIN BROKER NON-VOTE 1,884,258 631 0 N/A”

Estrella Immunopharma, Inc. shareholders approved Approve a proposed amended and restated certificate of incorporation of the post-Business Combination company at the 2023-07-31 meeting.

“The stockholders approved the proposal to approve, a proposed amended and restated certificate of incorporation (the “Proposed Charter”) of the post-Business Combination company (the “Combined Company”), which will amend and restate the Company’s current amended and restated certificate of incorporation (the “Current Charter”), which will be in effect upon the closing of the Business Combination (the “Closing”). The voting results were as follows: FOR AGAINT ABSTAIN BROKER NON-VOTE 1,884,258 631 0 N/A”

Estrella Immunopharma, Inc. entered into Binding Term Sheet with Suma Ventures, LLC valued at $6.8 million (effective 2023-07-25).

“On July 25, 2023, TradeUP Acquisition Corp. (the “Company” or “UPTD”) entered into a binding term sheet (the “Binding Term Sheet”) with Suma Ventures, LLC (the “Investor”), Estrella Biopharma, Inc., a Delaware corporation (“Estrella”), and Eureka Therapeutics, Inc., a Delaware corporation (“Eureka”), in connection with proposed transactions contemplated by a certain Agreement and Plan of Merger dated September 30, 2022 (the “Merger Agreement”) by and among UPTD, Estrella and Tradeup Merger Sub Inc. (such transactions, the “Business Combination”).”

Estrella Immunopharma, Inc. incurred loan of $50,000 with Tradeup INC. at no interest maturing upon the earlier to occur of (i) the consummation of the Business Combination or (ii) the date of expiry of the term of the Company.

“On July 20, 2023, TradeUP Acquisition Corp. (the “Company”) issued an unsecured promissory note (the “Promissory Note”) in the amount of $50,000 to Tradeup INC., one of the founders of the Company.”

Estrella Immunopharma, Inc.: Amended certificate of incorporation to extend business combination deadline from July 19, 2023 to July 14, 2024 (effective 2023-07-17).

“the Company filed a certificate of amendment to the Charter which became effective upon filing”

Estrella Immunopharma, Inc. shareholders approved Ratification of Marcum LLP as auditor at the 2023-07-17 meeting.

“The stockholders ratified the engagement of Marcum LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The voting results were as follows: FOR AGAINT ABSTAIN 2,055,472 105 0”

Estrella Immunopharma, Inc. shareholders approved Election of Class II directors at the 2023-07-17 meeting.

“The stockholders re-elected Mr. Tao Jiang and Mr. James as Class II directors of the Company to serve three-year term till the 2026 annual meeting of stockholders or until their successors are elected and qualified. The voting results were as follows: FOR WITHHOLD 1,906,559 8,596”

Estrella Immunopharma, Inc. shareholders approved Amend Investment Management Trust Agreement to extend liquidation date at the 2023-07-17 meeting.

“The stockholders approved the proposal to amend the Investment Management Trust Agreement, dated July 14, 2021, as amended on December 29, 2022, by and between the Company and Wilmington Trust, National Association, acting as trustee, to extend the liquidation date from July 19, 2023 to July 14, 2024 (the “Trust Amendment Proposal”). The voting results were as follows: FOR AGAINT ABSTAIN 1,908,849 6,306 0”

Estrella Immunopharma, Inc. shareholders approved Amend certificate of incorporation to extend business combination deadline at the 2023-07-17 meeting.

“The stockholders approved the proposal to amend the Company’s amended and restated certificate of incorporation to extend the date before which the Company must complete a business combination from July 19, 2023 to July 14, 2024 or such earlier date as determined by the board of directors of the Company (such extension is herein referred to as the “Extension”), and provide that the date for cessation of operations of the Company if the Company has not completed a business combination would similarly be extended (the “Extension Proposal”). Upon the stockholders’ approval, for each public share that is not redeemed by the stockholder in connection with the Extension, for each monthly period, or portion thereof during the Extension, the Company will deposit $0.05 per public share per month in the trust account. The voting results were as follows: FOR AGAINT ABSTAIN 1,908,849 6,306 0”

Estrella Immunopharma, Inc. amended Investment Management Trust Agreement with Wilmington Trust, National Association valued at extend the liquidation date from July 19, 2023 to July 14, 2024 (effective 2023-07-17).

“On July 17, 2023, TradeUP Acquisition Corp. (the “Company”) held a special meeting in lieu of its 2023 annual meeting of stockholders (the “Special Meeting”), where the stockholders of the Company approved the Company to, among others, amend the Investment Management Trust Agreement dated July 14, 2021, as amended on December 29, 2022 (the “Trust Agreement”), by and between the Company and Wilmington Trust, National Association (the “Trustee”) to extend the liquidation date from July 19, 2023 to July 14, 2024. Upon the stockholders’ approval, on July 17, 2023, the Company and the Trustee entered into the amendment to the Trust Agreement.”

Estrella Immunopharma, Inc. incurred convertible notes of $37,432.70 with Estrella Biopharma, Inc. at bears no interest maturing upon the consummation of the Company’s business combination.

“Such deposit is evidenced by an unsecured promissory note in the principal amount of $37,432.70 issued by the Company to Estrella (the “Extension Note”). The Extension Note bears no interest and is payable in full upon the consummation of the Company’s business combination (the “Business Combination”) (such date, the “Maturity Date”).”

Estrella Immunopharma, Inc. received a nasdaq deficiency notice notice regarding other (rules 5550(a)(3)).

“June 22, 2023, TradeUP Acquisition Corp. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Markets (“Nasdaq”) stating that the Nasdaq Staff had determined to grant the Company an extension of time through October 16, 2023 to regain compliance with Listing Rule 5550(a)(3) (the “Public Holder Rule”). As previously disclosed, the Company had received a separate written notice from Nasdaq stating that the Company did not meet the requirements of the Public Holder Rule. The Company submitted its plan of compliance on June 5, 2023 according”

Estrella Immunopharma, Inc. incurred loan of $45,511 with Estrella Biopharma, Inc. at no interest maturing upon the consummation of the Company's business combination.

“Pursuant to the Merger Agreement, Estrella has deposited a monthly extension payment of $45,511 to the trust account of the Company to extend the deadline for the Company to complete the business combination contemplated therein by July 19, 2023. Such deposit is evidenced by an unsecured promissory note in the principal amount of o $45,511 issued by the Company to Estrella (the “Extension Note”).”

Estrella Immunopharma, Inc. incurred loan of $60,000 with Tradeup INC. at no interest maturing upon the earlier to occur of (i) the consummation of the Business Combination or (ii) the date of expiry of the term of the Company.

“On June 6, 2023, TradeUP Acquisition Corp. (the “Company”) issued an unsecured promissory note (the “Promissory Note”) in the amount of $60,000 to Tradeup INC., one of the founders of the Company.”

Estrella Immunopharma, Inc. incurred loan of $45,511 with Estrella at no interest maturing upon the consummation of the Company's business combination.

“Estrella has deposited a monthly extension payment of $45,511 to the trust account of the Company to extend the deadline for the Company to complete the business combination contemplated therein by June 19, 2023. Such deposit is evidenced by an unsecured promissory note in the principal amount of o $45,511 issued by the Company to Estrella (the “Extension Note”).”

Estrella Immunopharma, Inc. amended Amendment to the Common Stock Purchase Agreement with White Lion Capital, LLC valued at $250,000 (effective 2023-04-26).

“Pursuant to the Amendment, the Company agrees that it will, immediately prior to the closing of the proposed business combination with Estrella Biopharma, Inc. (“Estrella”), cause Estrella to issue to White Lion an aggregate of 250,000 shares of Estrella’s Series A preferred stock, par value $0.0001 per share, which the parties have acknowledged has a value of $250,000.”

Estrella Immunopharma, Inc. entered into Registration Rights Agreement with White Lion Capital, LLC (effective 2023-04-20).

“Concurrently with the execution of the Common Stock Purchase Agreement, the Company entered into the RRA with the White Lion in which the Company has agreed to register with the SEC the shares of Common Stock purchased by White Lion under the Common Stock Purchase Agreement and the shares of Common Stock to be issued upon the conversion of Estrella Series A Preferred Stock for resale within 30 days of the consummation of the Business Combination.”

Estrella Immunopharma, Inc. entered into Common Stock Purchase Agreement with White Lion Capital, LLC valued at up to $50,000,000 (effective 2023-04-20).

“On April 20, 2023, TradeUP Acquisition Corp. (the “Company”) entered into a common stock purchase agreement (the “Common Stock Purchase Agreement”) and a related registration rights agreement (the “RRA”) with White Lion Capital, LLC, a Nevada limited liability company (“White Lion”).”

Estrella Immunopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(3)).

“April 19, 2023, TradeUP Acquisition Corp. (the “Company”) received a written notice (the “Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that the Company was not in compliance with Listing Rule 5550(a)(3) (the “Minimum Public Holders Rule”), which requires the Company to have at least 300 public holders for continued listing on the Nasdaq Capital Market. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the Nasdaq Ca”

Estrella Immunopharma, Inc. incurred loan of $45,511 with Estrella at no interest maturing upon the consummation of the Company's business combination.

“Estrella has deposited a monthly extension payment of $45,511 to the trust account of the Company to extend the deadline for the Company to complete the business combination contemplated therein by May 19, 2023. Such deposit is evidenced by an unsecured promissory note in the principal amount of o $45,511 issued by the Company to Estrella (the “Extension Note”).”

Estrella Immunopharma, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“April 3, 2023, TradeUP Acquisition Corp. (the “Company”) received a written notice (the “Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the Company’s minimum Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “Market Value Standard”). The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the”